Wyeth Earnings Jump 44% on Gain

The company noted that its hormone replacement family led by Premarin "continues to erode." Prescription trends "continue to decline," Martin said. "Given the trends that we currently see in this business, it is unlikely that revenue from the Premarin family will reach the $1.5 billion to $1.6 billion that we had forecast at the beginning of the year." Second-quarter sales were $277 million; half-year sales of the Premarin family were $679 million.

Martin added that unless Premarin prescription trends stabilize and hormone therapy trends continue to weaken, the company's growth trend "would be adversely affected."

Martin also pointed to the company's encouraging news -- strong growth for Effexor RX, for depression, and Protonix, a treatment for the esophagus caused by the backup of gastric acid from the stomach into the esophagus. Effexor XR produced $636 million in second-quarter sales, which Martin said kept the company "well on track to exceed our previously stated Effexor sales goal of $3 billion next year." Protonix recorded $300 million in sales for the second quarter, up 62% from the same period last year.

« Previous Page

1 2

Next Page »